Tempus ECG-Low EF vs Cardiomo
AI Verdict
Choose Tempus ECG-Low EF if…
Choose Tempus ECG-Low EF if your healthcare facility needs an FDA-cleared AI software to analyze existing 12-lead ECG recordings for patients 40 years or older at risk of heart failure, specifically to detect signs associated with low left ventricular ejection fraction (LVEF ≤40%). This tool is ideal for aiding clinicians in further in-facility evaluation and identifying patients who may require additional diagnostic workup, such as an echocardiogram.
View Tempus ECG-Low EF →Choose Cardiomo if…
Choose Cardiomo if you require a medical-grade wearable device and an AI-powered platform for continuous and remote heart health monitoring, particularly for detecting cardiovascular diseases and providing timely alerts to users, caregivers, and medical professionals. This tool is well-suited for ongoing patient monitoring outside of a clinical setting, offering features like real-time ECG, heart rate, respiration, skin temperature, fall detection, and mobile app integration for alerts and data dashboards.
View Cardiomo →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-Low EF | Cardiomo |
|---|---|---|
| Pricing | Contact vendor | Contact for pricing |
| Deployment | Software, integrated into healthcare facility workflows | Cloud-based with wearable device and mobile app |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | Unknown |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
CardiomoCardiomo offers a wearable patch and mobile app for continuous, remote monitoring, making it highly accessible and user-friendly for patients in their daily lives. Tempus ECG-Low EF, while integrated into clinical workflows, is designed for use within healthcare facilities and does not offer the same level of direct patient usability or continuous monitoring outside of a clinical setting.
Clinical Value
Tempus ECG-Low EFTempus ECG-Low EF is an FDA-cleared software that analyzes 12-lead ECGs to detect signs of low LVEF, a critical indicator for heart failure, and has been clinically validated with high sensitivity and specificity. Cardiomo, while offering continuous monitoring and alerts for cardiovascular events, is a wearable device that has received ISO 13485 certification and is pursuing FDA approval, but its clinical validation studies are not as extensively detailed or publicly available as Tempus ECG-Low EF's.
Pricing & Value
TieBoth tools require contacting the vendor for current pricing, making a direct comparison difficult. Cardiomo previously offered a device for $200 with a $10 monthly subscription, but this pricing is not current. Without transparent and up-to-date pricing for either, it's impossible to definitively determine which offers better value.
Enterprise Readiness
Tempus ECG-Low EFTempus ECG-Low EF is designed for integration into existing healthcare facility workflows and EHR systems, indicating a strong focus on enterprise deployment and scalability within clinical environments. Tempus AI as a company is a larger, publicly traded entity with a broader precision medicine platform. Cardiomo is a smaller company with a focus on remote patient monitoring, and while it mentions HIPAA compliance and cloud analytics, its enterprise integration capabilities are not as explicitly detailed.
Innovation
TieBoth tools demonstrate innovation in their respective approaches to cardiac care. Tempus ECG-Low EF utilizes advanced AI for retrospective analysis of standard ECGs to identify a specific, critical condition (low LVEF). Cardiomo innovates with its medical-grade wearable for continuous, real-time remote monitoring and AI-powered alerts, offering a proactive and patient-centric approach.
Support & Docs
TieNeither the provided structured facts nor the web search results offer specific details regarding the level of customer support, training, or documentation available for either Tempus ECG-Low EF or Cardiomo. Therefore, it is not possible to pick a winner in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-Low EF | Cardiomo |
|---|---|---|
| Tool Name | Tempus ECG-Low EF | Cardiomo |
| Company | Tempus AI | Cardiomo, Inc. |
| Description | FDA-cleared AI software that analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure. It provides a binary output to aid clinicians in further evaluation. | Medical-grade wearable device and an AI-powered platform for continuous and remote heart health monitoring, designed to detect cardiovascular diseases and provide timely alerts to users and caregivers. |
| Key Features | AI-powered algorithm for ECG analysis; Detects signs of low Left Ventricular Ejection Fraction (LVEF u226440%); Analyzes resting, non-ambulatory 12-lead ECG recordings; Provides a binary output (Low LVEF Detected / Not Detected); Aids in identifying patients 40+ years at risk of heart failure; Trained on a large dataset of over 930,000 ECGs from 170,000+ patients; Intended for use in clinical diagnostic settings at healthcare facilities | Medical-grade wearable patch; Continuous vital sign monitoring (ECG, heart rate, respiration, skin temperature); AI-powered disease detection (arrhythmias, cardiovascular events); Real-time alerts and notifications; Mobile application (Android and iOS); HIPAA-compliant cloud analytics; Fall detection; Long battery life (up to 7-10 days) |
| Specialties | Cardiology, Emergency Medicine, Internal Medicine | Cardiology, Geriatrics, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-Low EF and Cardiomo.
More Comparisons
More matchups featuring Tempus ECG-Low EF or Cardiomo
Backers
Who funded each tool's parent company.